Drug intelligence / Profile preview

GR1016

Development stage: Preclinical
Lead developer: GeneQuantum Biosciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GR1016 is an investigational antibody-drug conjugate (ADC) developed by GeneQuantum Healthcare. It is engineered using the company's proprietary intelligent Ligase Dependent Conjugation (iLDC) technology, an enzymatic site-specific conjugation platform designed to produce highly homogeneous ADCs. This approach aims to improve the stability, safety, and therapeutic index of the drug compared to conventional random conjugation methods. While GR1016 is a confirmed candidate within GeneQuantum's oncology-focused pipeline, its specific molecular target and primary clinical indications remain undisclosed by the developer.

Beyond the preview

Go deeper on GR1016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GR1016.

Explore the full profile